Table 2 Mechanisms of action: latrepirdine

From: Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases

Cellular target/pathway

Drug activity

Reference

Ion channels and receptor activity

Inhibits voltage-gated calcium channels

Interacts with L-type Ca2+ channel, sodium channel, hERG potassium channel and transporter for norepinephrine

Blocks histamine receptor (H1 and H2) activity

Inhibits NMDA receptors and potentiates activity of AMPA-receptors

Inhibits α-adrenergic receptors (α1A, α1B, α1D, and α2A), imidazoline I2 receptor and serotonin 5-HT2c, 5-HT5A, 5-HT6 receptors

5

17

6, 7

37

17

Mitochondrial activity

Modulate the mitochondrial PTP and suppresses opening of PTP induced by neurotoxins

Attenuates Ca2+-induced mitochondrial swelling

Improves mitochondrial function on aspects such as mitochondrial membrane potential and ATP synthesis

Protects mitochondrial membrane integrity

Enhanced CGU in aged mice

Restore the toxic effects of Aβ on mitochondrial morphology, respiratory chain complex and enlarged mitochondrial mass

39

68

18

19

70

69

Protein aggregation

Reduces the number of TDP-43 aggregates in neuroblastoma cells

Reduces the number of amyloid deposits in the spinal cord of over expressing γ-synuclein mice

Reduces accumulation of hippocampal/subicular APP/Aβ and α-synuclein in mice

Elevates secretion of Aβ in the extracellular media in neuronal cells and AD transgenic mice

Reduces GFP-Aβ42 in wild-type compared with the autophagy-deficient mutant (Atg8Δ) in yeast model

74

14

20, 21, 22

76

55

Protein degradation pathways

Upregulates autophagic markers in yeast model

Enhances mTOR- and Atg5-dependent autophagy cultured mammalian cells

Shows increased UPS activity in over expression γ-synuclein mice model

55

22

75

Neuroprotective functions

Inhibits MAO deaminating dopamine and serotonin, decrease dopamine metabolism and increase noradrenaline level in the rat brain

Inhibits of both acetylcholine esterase and butyrylcholine esterase.

Restores TWAA performance in rats injected with AF64A

Prevents development of convulsions and death caused by NMDA induced toxicity in mice

Reduces amphetamine induced striatal dopamine depletion in mice and promote hippocampus-dependent learning in both appetitive and inhibitory tasks in mice

Enhance memory and learning in a primate model

Increases hippocampal neurogenesis in the mouse model

Reduces the development of motor dysfunction in overexpressing synuclein mice model

Improves spatial memory function and behaviour in AD transgenic mice

Protects cultured cells against Aβ toxicity

46

47

15

5

50

52

19

14

22

5, 18, 55

  1. Abbreviations: Aβ, β-amyloid; AD, Alzheimer’s disease; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; Atg5, autophagy-related protein 5; CGU, cerebral glucose utilization; hERG, human ether-a-go-go-related gene; MAO, monoamine oxidase; mTOR, mammalian target of rapamycin; NMDA, N-methyl-D-aspartate PTP, permeability transition pore; TDP-43, TAR DNA-binding protein 43; TWAA, two-way active avoidance; UPS, ubiquitin proteosome.